The goal of the Mayo SPORE In Brain Cancer Developmental Research Program (DRP) is to support innovative and scientifically sound projects that investigate questions pertaining to some aspect of translational research in malignant gliomas and other primary brain tumors. The DRP will provide two one year awards of $50,000 each. Dr. Robert B. Jenkins, overall Co-PI of the SPORE, will direct the program. The premise of this program is that support of developmental research projects will result in the generation of new hypotheses that will be tested within SPORE-sponsored projects or through peer-reviewed external grant support. The long-term goal of the program Is to translate the findings generated by developmental grants into effective interventions in patients with, and persons at risk for, primary brain tumors. An equally important goal is the attraction of new Investigators and their expertise to the challenges of brain cancer research. The DRP objectives are to: (1) stimulate Innovative and translationally-relevant laboratory, population science and clinical studies in primary brain tumors;(2) foster extensive collaboration between basic science, population science and clinical disciplines to advance brain tumor translational research, and (3) encourage investigators in related fields to apply their expertise to translational research in brain tumors. The Program will be administered through the Administrative Core of the SPORE. One-page outlines of two potential research projects are included to demonstrate the depth and breadth of ongoing research that can be eligible for funding through the SPORE Developmental Research Program. These two potential projects represent under-developed areas within glioma research.

Public Health Relevance

The Mayo SPORE in Brain Cancer Developmental Research Program was established to fund early phase research that take maximum advantage of SPORE resources to generate feasibility data for projects that have the highest translational potential. In so doing the DRP will develop scientists who will advance and significantly impact the nation's brain tumor agenda.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Oi, N; Yuan, J; Malakhova, M et al. (2015) Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1. Oncogene 34:2660-71
Choi, Jae Won; Schroeder, Mark A; Sarkaria, Jann N et al. (2014) Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells. Cancer Res 74:484-96
Bradley, Barrie S; Loftus, Joseph C; Mielke, Clinton J et al. (2014) Differential expression of microRNAs as predictors of glioblastoma phenotypes. BMC Bioinformatics 15:21
Walsh, Kyle M; Codd, Veryan; Smirnov, Ivan V et al. (2014) Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46:731-5
Bell, Michael P; Renner, Danielle N; Johnson, Aaron J et al. (2014) An elite controller of picornavirus infection targets an epitope that is resistant to immune escape. PLoS One 9:e94332
Catteau, Aurélie; Girardi, Hélène; Monville, Florence et al. (2014) A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Commun 2:58
Johnson, Holly L; Jin, Fang; Pirko, Istvan et al. (2014) Theiler's murine encephalomyelitis virus as an experimental model system to study the mechanism of blood-brain barrier disruption. J Neurovirol 20:107-12
Gupta, Shiv K; Mladek, Ann C; Carlson, Brett L et al. (2014) Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 20:3730-41
Assefnia, Shahin; Dakshanamurthy, Sivanesan; Guidry Auvil, Jaime M et al. (2014) Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget 5:1458-74
Wang, Enfeng; Zhang, Chunyang; Polavaram, Navatha et al. (2014) The role of factor inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. PLoS One 9:e86102

Showing the most recent 10 out of 103 publications